Amvuttra Injection
Product Images NDC 71336-1003

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Amvuttra (NDC 71336-1003). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alnylam Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Amvuttra 01)

Illustration diagram of a subcutaneous injection syringe for Amvuttra (vutrisiran) 25 mg/0.5 mL. The labeled parts include needle cap, needle, drug solution, syringe body, syringe label, finger flange, plunger rod, and thumb pad, showing the components of the injection device.*

FDA Label Image

Image (Amvuttra 02)

An instructional illustration showing a subcutaneous injection device for AMVUTTRA (vutrisiran). The image highlights the needle shield in a locked position, with a detailed view of the syringe and locking mechanism in red and gray colors.*

FDA Label Image

Image (Amvuttra 03)

Illustration showing front and back views of a human figure with shaded areas indicating preferred subcutaneous injection sites. Highlighted sites include the abdomen, upper thigh, and upper outer arm regions, relevant for administering subcutaneous injections like AMVUTTRA (VUTRISIRAN).*

FDA Label Image

Image (Amvuttra 04)

An instructional diagram showing two hands preparing a syringe for injection. One hand holds the syringe while the other removes the protective cap from the needle, indicated by an arrow pointing upward.*

FDA Label Image

Image (Amvuttra 05)

An instructional illustration showing a hand holding a syringe poised for subcutaneous injection at a 45-degree angle, with the other hand pinching the skin at a 90-degree angle, indicating proper injection technique.*

FDA Label Image

Image (Amvuttra 06)

An instructional illustration showing a hand holding a subcutaneous injection device with a safety shield being activated or removed, indicated by an arrow. The image relates to the preparation or administration steps for AMVUTTRA (vutrisiran) injection.*

FDA Label Image

Image (Amvuttra 07)

An instructional illustration showing a hand holding a prefilled syringe injection device. The image depicts the syringe being positioned for subcutaneous injection, with an arrow indicating the plunger is being pushed to administer the dose.*

FDA Label Image

Chemical Structure (Amvuttra 08)

Chemical structure diagram of Vutrisiran showing the sense and antisense strands with labeled nucleotide units and phosphate linkages, indicating the positions of sulfur atoms and sodium ions.*

FDA Label Image

Chemical Formula (Amvuttra 09)

Chemical structure of the active ingredient VUTRISIRAN, showing a complex molecular diagram with carbohydrate and peptide components labeled as R1.*

FDA Label Image

Figure 1 (Amvuttra 10)

A line graph comparing the least squares mean change in mNIS+7 score from baseline to month 9 between AMVUTTRA and placebo groups. The placebo group shows an increase in score, while the AMVUTTRA group shows a decrease. The graph includes sample sizes for each group at baseline and month 9 and statistical significance data for the difference between groups.*

FDA Label Image

Figure 2 (Amvuttra 11)

A bar chart comparing the percent of patients receiving AMVUTTRA (vutrisiran) versus placebo. The x-axis shows change from baseline to month 9 in mNIS+7 scores, ranging from less than -40 to greater than 70, including categories for death and missing data. The y-axis indicates the percent of patients. Bars reveal distribution differences between the AMVUTTRA group and placebo group, with annotations "Better" and "Worse" indicating direction of change.*

FDA Label Image

Figure 3 (Amvuttra 12)

A line graph showing the least squares mean change in Norfolk QoL-DN Total Score from baseline to month 9 for AMVUTTRA and placebo groups. The placebo group's score increased to 12.9, while the AMVUTTRA group's score decreased to -3.3, indicating a significant difference between the two treatments. Sample sizes are noted for placebo and AMVUTTRA groups at baseline and month 9.*

FDA Label Image

Figure 4 (Amvuttra 13)

A bar chart comparing percent of patients between placebo (N=77) and AMVUTTRA (N=118) groups showing changes from baseline to month 9 in the Norfolk QoL-DN total score. The x-axis categorizes score changes from negative (better) through zero to positive (worse), and includes death/missing data. The y-axis shows percent of patients. AMVUTTRA group has higher percentages in the better range (negative changes) compared to placebo, while placebo shows higher percentages in the worse range and in death/missing.*

FDA Label Image

Principal Display Panel (25 mg Syringe Carton)

Packaging label for AMVUTTRA (vutrisiran) injection, 25 mg/0.5 mL. The label is for a single-dose prefilled syringe intended for subcutaneous injection by healthcare professionals. Labeler is Alnylam Pharmaceuticals, Inc. The NDC is 71336-1003-1. The label includes dosing strength, usage instructions, and storage guidance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.